Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, MD PhD, Roberto E. Cacchione, MD, Wojciech Jurczak, MD PhD, Cheolwon Suh, Lorenz Truemper, MD, Christian W Scholz

Blood (2019) 134 (Supplement_1): 5263.

https://doi.org/10.1182/blood-2019-124192

Published: 2019

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

Efficacy of Yttrium-90 Iburitumomab Tiuxetan for Early Relapsed/Refractory Indolent B-Cell Lymphoma: A Single Institute Retrospective Analysis in the Rituximab Era

Keiichi Nakata, MD, Shigeo Fuji, MD PhD, Ryo Nakata, MD, Kazuhito Tsutsumi, MD, Shuhei Kida, MD, Midori Koike, MD, Yuma Tada, MD, Hiroaki Masaie, MD, Hitoshi Yoshida, MD, Jun Ishikawa, MD PhD

Blood (2018) 132 (Supplement 1): 5333.

https://doi.org/10.1182/blood-2018-99-112782

Published: 2018

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Blood (2018) 132 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2018-99-117767

Published: 2018

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Issa F. Khouri, MD, Bill Erwin, MS, Alison M Gulbis, PharmD, Francesco Turturro, MD, S Cheenu Kappadath, PhD, Dustin Gress, MS, Rosamar B Valverde, Elias J. Jabbour, MD, Roland L Bassett, Jr., Aaron Jessop, MBA,MD

Blood (2016) 128 (22): 662.

https://doi.org/10.1182/blood.V128.22.662.662

Published: 2016

Journal Articles

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Blood (2015) 126 (23): 118.

https://doi.org/10.1182/blood.V126.23.118.118

Published: 2015

Journal Articles

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert Chen, Joycelynne Palmer, PhD, Peter Martin, MD, Saro Armenian, DO, MPH, Nichun Tsai, Michelle Mott, Firoozeh Sahebi, Ji-Lian Cai, MD PhD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Auayporn P. Nademanee, MD, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 519.

https://doi.org/10.1182/blood.V126.23.519.519

Published: 2015

Journal Articles

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert W Chen, MD, Joycelynne Palmer, PhD, Peter Martin, MD, Nicole Tsai, Young Kim, MD, Michelle Mott, RN, Firoozeh Sahebi, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Tsiporah B. Shore, Stephen J. Forman

Blood (2014) 124 (21): 501.

https://doi.org/10.1182/blood.V124.21.501.501

Published: 2014

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

A Phase 2 Open-Label Safety and Tolerability Study of Single Intravenous (IV) Escalating Doses of 90 Yttrium-Labeled Antiferritin Antibodies ( 90 Y-Antiferritin) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Didier Decaudin, MD, Alain Pecking, MD, François Lokiec, PhD, Jean Kadouche, PhD, Stephane E. Allard, MD

Blood (2014) 124 (21): 5468.

https://doi.org/10.1182/blood.V124.21.5468.5468

Published: 2014

Journal Articles

FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90 yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases

Francesco Pisani, Member, ID:, 1012314, Maria Laura Dessanti, MD, Diana Giannarelli, MS, Ramy Kayal, MD, Francesco Marchesi, MD, Rosa Sciuto, MD, Sandra Rea, MD, Carlo Ludovico Maini, MD, Mirella Marino, MD

Blood (2014) 124 (21): 5452.

https://doi.org/10.1182/blood.V124.21.5452.5452

Published: 2014

Journal Articles

Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkgin’s Lymphoma

Marielle J Wondergem, MD, Theresia M Westers, PhD, Otto Visser, MDhD, Josee M Zijlstra, Sonja Zweegman, MD PhD, Martine ED Chamuleau, MD

Blood (2014) 124 (21): 5882.

https://doi.org/10.1182/blood.V124.21.5882.5882

Published: 2014

Journal Articles

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Aimee L. Kenoyer, BS, Yukang Lin, PhD, Johnnie J. Orozco, MD PhD, Ethan Balkin, Don Hamlin, BS, Alexandra H. Hernandez, BS, Chen Fang, PhD, Kelly Laird, Sofia H.L. Frost, PhD, Mark Hylarides, PhD, Kelly D. Orcutt, PhD, D Scott Wilbur, PhD, K. Dane Wittrup, PhD, Oliver W. Press, MD PhD, John Pagel, MD PhD

Blood (2014) 124 (21): 3749.

https://doi.org/10.1182/blood.V124.21.3749.3749

Published: 2014

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Patrice Chevallier, MD, PhD, Caroline bodet-Milin, MD, Nelly Robillard, Thomas Eugene, MD, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, MD, Jacques Delaunay, MD, Martine Escoffre-Barbe, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD, Françoise kraeber-Bodere, MD

Blood (2013) 122 (21): 3910.

https://doi.org/10.1182/blood.V122.21.3910.3910

Published: 2013

Journal Articles

90 Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

Katharina Troppan, MD, Angelika Valentin, MD, Werner Linkesch, MD

Blood (2013) 122 (21): 5123.

https://doi.org/10.1182/blood.V122.21.5123.5123

Published: 2013

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

NARROW

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Efficacy of Yttrium-90 Iburitumomab Tiuxetan for Early Relapsed/Refractory Indolent B-Cell Lymphoma: A Single Institute Retrospective Analysis in the Rituximab Era

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

A Phase 2 Open-Label Safety and Tolerability Study of Single Intravenous (IV) Escalating Doses of 90 Yttrium-Labeled Antiferritin Antibodies ( 90 Y-Antiferritin) in Patients with Relapsed or Refractory Hodgkin Lymphoma

FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90 yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases

Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkgin’s Lymphoma

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

90 Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only